Arbutus Biopharma Corp
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation British Columbia, Canada
Business Address 701 VETERANS CIRCLE, WARMINSTER, PA, 18974
Mailing Address 701 VETERANS CIRCLE, WARMINSTER, PA, 18974
Phone 604-419-3200
Fiscal Year End 1231
EIN 980597776
Financial Overview
FY2024
$38.38M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 11, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 16, 2026 | View on SEC |
| 8-K Current report of material events | December 11, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| 8-K Current report of material events | October 7, 2025 | View on SEC |
| 8-K Current report of material events | September 10, 2025 | View on SEC |
Material Events
8-K Legal Issue January 16, 2026
High Impact
- The European patent revocation is limited to Europe and does not affect Arbutus's litigation efforts in the U.S., Japan, Canada, or other UPC cases.
- Arbutus maintains a broader, diversified intellectual property strategy across various jurisdictions.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.